Nutriband Inc. Signs Exclusive License Agreement with RAMBAM Hospital Group for its Closed System Transfer Device

Orlando, FL –  December 15, 2020 – Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, announced that it signed an exclusive license agreement with RAMBAM Med Tech Ltd, a Division of the RAMBAM Hospital, the largest medical center in Northern Israel, for its Closed System Transfer Device designed to liquify drugs for patients who cannot swallow solids.


The Closed System Transfer Device or CSTD combines the act of crushing a solid drug, dissolving in liquid and giving to a patient who cannot swallow for various reasons.  The single-use device mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system making the delivery technology both safe for patients and medical professionals, particularly when seeking to liquify or dissolve hazardous drugs.


Following the signing of the exclusive license agreement with RAMBAM, the company plans to develop and file for 510K approval in the United States in the coming months.


The licensing of RAMBAM’s CSTD device compliments the goal and pipeline of Nutriband Inc., which is to improve safety, comfort, and efficacy for the patient, primarily targeting already approved drugs to improve patient outcomes.


About Nutriband Inc.


The Company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is its abuse deterrent fentanyl transdermal system which the Company is developing to provide clinicians and patients with an abuse deterrent transdermal fentanyl product for use in managing chronic pain requiring opioid therapy.  The product is combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches.


The Company’s website is


4P’s (Subsidiary) website is


Pocono Pharma’s (Subsidiary) website is


Any material contained in or derived from any of the company’s websites or any other website is not part of this press release.


About Our Forward-Looking Statements


Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” plans and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop  products and conduct the necessary clinical testing, its ability obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized development stage company that does not have a product that can be marketed and the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form 10-K for the year ended January 31, 2020 and under “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” in the Company’s Form 10-Q for the six months ended July 31, 2020, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date hereof.


For more information, contact:

Victor Roberts
Red Chip Companies


Gerald Weigel

Public Relations Principal

Nutriband Inc.

Nutriband Office: 407-377-6695

Direct: 419-304-6300



Source: Nutriband Inc.